Endospan stories one-year TRIOMPHE examine outcomes for the NEXUS system

The most recent FDA recognition is supported by constructive outcomes from a number of research, together with two replicated Section III research. Credit score: Motortion Movies / Shutterstock.com.

Endospan has introduced constructive one-year outcomes from the TRIOMPHE examine evaluating the NEXUS aortic arch stent graft system.

The multicenter, three-arm, potential examine assessed the effectiveness and security of the system in sufferers with aneurysm, dissection, and penetrating aortic ulcer (PAU)/intramural hematoma (IMH).

Uncover B2B advertising and marketing that delivers

Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.

Extra info

The one-year knowledge covers 94 sufferers at excessive surgical threat throughout all arms, specializing in therapy in zone 0 of the aorta, a posh phase with related dangers resembling dying and stroke.

Core laboratory analyzes revealed no kind III or IV endoleaks, with solely three sufferers experiencing Ia or Ib endoleaks, indicating seal over 12 months.

These outcomes are vital given the challenges in treating thoracic aortic arch illness, which impacts greater than 120,000 sufferers yearly in Europe and the US. Solely 25% of those sufferers are recognized or handled.

Open surgical restore of the aortic arch nonetheless results in excessive mortality and morbidity charges. Many sufferers will not be appropriate for surgical procedure because of perioperative dangers or anatomical issues. The shortage of authorised endovascular arch units limits minimally invasive choices, making therapy selections tough for some people.

Within the US, the NEXUS system is awaiting pre-market approval (PMA) evaluation by the Meals and Drug Administration (FDA). Availability exterior the US is topic to native rules and pointers.

Kevin Mayberry, CEO of Endospan, stated: “NEXUS is particularly designed for the overall aortic arch. We’re happy to see that the one-year knowledge for the TRIOMPHE examine is in line with the pre- and post-commercialization knowledge printed in Europe.

“The TRIOMPHE knowledge continues to assist NEXUS as a easy, minimally invasive resolution for aortic arch restore that permits procedural consistency with dependable affected person outcomes.”

In October 2024, Endospan accomplished enrollment within the main arm of a scientific trial evaluating the stent graft for the therapy of aortic arch illness.